Aditxt, Inc.ADTXEarnings & Financial Report
Aditxt, Inc. is a clinical-stage biotechnology company focused on immunology. It develops targeted therapies to promote immune tolerance for patients with autoimmune diseases and organ transplant recipients, plus immune monitoring technologies. Its main markets are in North America, with expansion efforts underway in other global developed healthcare regions.
Revenue
$81.3K
Gross Profit
$-204.6K
Operating Profit
$-8.0M
Net Profit
$-11.1M
Gross Margin
-251.6%
Operating Margin
-9780.0%
Net Margin
-13679.4%
YoY Growth
-56.2%
EPS
$-24998.07
Aditxt, Inc. Q4 FY2023 Financial Summary
Aditxt, Inc. reported revenue of $81.3K (down 56.2% YoY) for Q4 FY2023, with a net profit of $-11.1M (down 35.9% YoY) (-13679.4% margin). Cost of goods sold was $285.9K, operating expenses totaled $7.7M.
Key Financial Metrics
| Total Revenue | $81.3K |
|---|---|
| Net Profit | $-11.1M |
| Gross Margin | -251.6% |
| Operating Margin | -9780.0% |
| Report Period | Q4 FY2023 |
Aditxt, Inc. Annual Revenue by Year
Aditxt, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $645.2K).
| Year | Annual Revenue |
|---|---|
| 2023 | $645.2K |
| 2022 | $933.7K |
Aditxt, Inc. Quarterly Revenue & Net Profit History
Aditxt, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $44.3K | -80.0% | $-7.5M | -17051.3% |
| Q1 FY2024 | $79.7K | -63.5% | $-14.7M | -18486.1% |
| Q4 FY2023 | $81.3K | -56.2% | $-11.1M | -13679.4% |
| Q3 FY2023 | $124.5K | -61.5% | $-9.9M | -7963.2% |
| Q2 FY2023 | $221.0K | +2.9% | $-5.7M | -2571.3% |
| Q1 FY2023 | $218.4K | +3.9% | $-6.0M | -2740.1% |
| Q4 FY2022 | $185.6K | — | $-8.2M | -4409.1% |
| Q3 FY2022 | $323.1K | — | $-7.6M | -2338.9% |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $323125 | $185596 | $218415 | $220978 | $124486 | $81297 | $79680 | $44276 |
| YoY Growth | N/A | N/A | 3.9% | 2.9% | -61.5% | -56.2% | -63.5% | -80.0% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $19.2M | $10.7M | $7.6M | $7.3M | $8.2M | $44.6M | $28.0M | $28.4M |
| Liabilities | $6.5M | $5.5M | $7.6M | $11.2M | $12.4M | $28.5M | $18.2M | $22.0M |
| Equity | $12.7M | $5.2M | $68068 | $-3.9M | $-4.2M | $16.1M | $9.9M | $6.6M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.8M | $-6.7M | $-4.0M | $-3.3M | $-8.0M | $-3.9M | $-6.0M | $-2.3M |